8:00 am Check-In & Light Breakfast

8:55 am Chair’s Opening Remarks

Bridging Drug Substance & Product Development to Optimize Steps in Pharmaceutical Formulation

9:00 am The Final Touch: Balancing Stability, Efficiency & Innovation for Fast-Tracked ADC Drug Product Delivery

  • Rupesh Nanjunda Associate Director, Biologics Drug Product Development, Johnson & Johnson

Synopsis

  • Determining the best format for ADC delivery to ensure stability and minimize wastage in earlier stages
  • Focusing on the composition and concentration of ADCs to achieve the best formulation for bringing the drug product to the clinic
  • Collaborating with the drug substance team to address challenges surrounding conjugation platforms upfront for the optimal drug product

Standardizing Our Risk Assessment to Create Safer Environments for Better Occupational Health

9:30 am Addressing Complex Challenges of Ensuring Occupational Health & Safety for Multi-Stakeholders

Synopsis

  • Overcoming hurdles with facilitating occupational health and safety standards when working with high potency compounds
  • Communicating occupational band criteria with CMOs/CDMOs to seek alignment with BMS’ protocols
  • Exploring solutions for handling high potency compounds during early research phase to translate knowledge into later development stages

10:00 am Morning Refreshments & Networking

11:00 am Mastering Process Safety: Eliminating Risks in the Design & Management of Facilities for HPAPIs

  • Omid ZadakBar Senior Manager, Global EHS Design Engineering, Amgen

Synopsis

  • Navigating through the engineering challenges of handling HPAPIs, biologics, flammables, and other HHMs while maintaining safety for workers and the environment
  • Integrating RBPS elements into all phases of the engineering capital projects
  • Highlighting key safety considerations when working with CDMOs from both client and contractor perspective
  • Advancing our knowledge of RAGAGEP and applying the concept in design and management of facilities for HPAPI

11:30 am Roundtable Discussion: Putting Safety Above All: Developing Risk Assessment Protocols to Ensure Worker Safety & Health in Their Day-to-Day Handling of High Potency Drugs

Synopsis

Our 45-minute roundtable discussion will focus on developing consistent frameworks for risk assessment in occupational exposure when handling high potency compounds, with a strong emphasis on protecting workers and maintaining health in contained environments:

  • Discussing best practices for consistently assessing and classifying occupational exposure bands for high potency compounds to ensure that all teams adhere to established safety standards
  • Sharing strategies for creating and maintaining controlled environments including containment systems and engineering controls to prevent exposure
  • Examining ways to integrate robust health monitoring programs and compliance measures to promote long-term well-being of workers while adhering to occupational safety regulations

12:30 pm Lunch & Networking

1:30 pm Transferrable Insights & Best Practices: Safe Handling of Potent Compounds From R&D to Pilot

Synopsis

  • Understanding key safety considerations when handling potent compounds during R&D scale-up
  • Sharing real practices of implementing safety measures for advancing from small-scale lab work (10mg) to pilot scale (50kg)
  • Engineering novel solutions to maintain a safe work environment when handling potent compounds

Integrating Green Chemistry to Transform Our Environmental Impact for Sustainable Practices

2:00 pm Tackling Uncertainty: Targeted Risk Assessment & Management for High-Quality HPAPI

  • Naiffer Romero Principal Scientist, Scientific Affairs, US Pharmacopeia

Synopsis

  • Building a step-by-step guide on how to create quality standards for impurity manufacturing
  • Spotlighting US Pharmacopeia’s approach to handling various impurities in-house
  • Leveraging our symbiotic relationship with the FDA to minimize risk based on the evolving regulatory landscape

2:30 pm Chair’s Closing Remarks

2:45 pm End of Conference Day Two